The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Nivolumab-AVD versus BV-AVD in Hodgkin lymphoma
Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, briefly discusses the benefits of nivolumab-AVD compared to brentuximab vedotin (BV)-AVD in treating patients with Hodgkin lymphoma, particularly older patients, where nivolumab-AVD shows a significant progression-free survival and evolving overall survival benefit. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
